LV12859B - Pharmaceutical formulations and methods comprising intranasal morphine - Google Patents

Pharmaceutical formulations and methods comprising intranasal morphine Download PDF

Info

Publication number
LV12859B
LV12859B LVP-01-169A LV010169A LV12859B LV 12859 B LV12859 B LV 12859B LV 010169 A LV010169 A LV 010169A LV 12859 B LV12859 B LV 12859B
Authority
LV
Latvia
Prior art keywords
morphine
acceptable salt
pharmaceutically acceptable
absorption
pharmaceutical composition
Prior art date
Application number
LVP-01-169A
Other languages
English (en)
Latvian (lv)
Inventor
Raja G. Achari
Charanjit R. BEHL
Jorge C. Demeireles
Ramneik Dua
Vincent D. ROMEO
Anthony P. Sileno
Original Assignee
Nastech Pharmaceutical Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharmaceutical Co., Inc. filed Critical Nastech Pharmaceutical Co., Inc.
Publication of LV12859B publication Critical patent/LV12859B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LVP-01-169A 1999-06-16 2002-01-18 Pharmaceutical formulations and methods comprising intranasal morphine LV12859B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
LV12859B true LV12859B (en) 2002-12-20

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-169A LV12859B (en) 1999-06-16 2002-01-18 Pharmaceutical formulations and methods comprising intranasal morphine

Country Status (30)

Country Link
US (1) US6677346B1 (is)
EP (2) EP1183027A4 (is)
JP (1) JP2003501467A (is)
KR (1) KR20020016831A (is)
AU (1) AU774175B2 (is)
BG (1) BG106221A (is)
BR (1) BR0012082A (is)
CA (1) CA2374877C (is)
CZ (1) CZ20014399A3 (is)
DE (1) DE10084709T1 (is)
DK (1) DK200101859A (is)
EE (1) EE200100677A (is)
ES (1) ES2197792B1 (is)
FI (1) FI20012462A7 (is)
GB (1) GB2367005A (is)
HR (1) HRP20010926A2 (is)
HU (1) HUP0201856A3 (is)
IS (1) IS6202A (is)
LT (1) LT4976B (is)
LU (1) LU90859B1 (is)
LV (1) LV12859B (is)
MX (1) MXPA01012879A (is)
NO (1) NO20015931L (is)
NZ (1) NZ515783A (is)
PL (1) PL352556A1 (is)
SE (1) SE0104203L (is)
SI (1) SI20850A (is)
SK (1) SK18172001A3 (is)
TR (1) TR200103613T2 (is)
WO (1) WO2000076506A1 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
EP1418862A4 (en) * 2001-06-29 2010-06-09 Leon J Lewandowski INDIVIDUALIZED SEARCH THERAPY
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007338210B2 (en) * 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
HRP20180233T1 (hr) 2011-05-13 2018-06-01 Euro-Celtique S.A. Intranazalni farmaceutski oblici doziranja koji sadrže nalokson
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
EP3528797A1 (en) * 2016-10-21 2019-08-28 Somniferum Labs LLC Compositions, methods and kits for the safe inhaled delivery of targeted opioids for the treatment of pain and addiction
MA50394A (fr) * 2017-10-20 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
CA2266898A1 (en) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Co., Inc. Intranasal formulations for promoting sleep and method of using the same

Also Published As

Publication number Publication date
NO20015931L (no) 2002-02-08
EE200100677A (et) 2003-02-17
US6677346B1 (en) 2004-01-13
CA2374877A1 (en) 2000-12-21
MXPA01012879A (es) 2003-06-24
PL352556A1 (en) 2003-08-25
HUP0201856A3 (en) 2004-12-28
GB2367005A (en) 2002-03-27
LT4976B (lt) 2002-12-30
GB0128383D0 (en) 2002-01-16
AU5156100A (en) 2001-01-02
SE0104203D0 (sv) 2001-12-14
CZ20014399A3 (cs) 2002-06-12
EP1183027A1 (en) 2002-03-06
DK200101859A (da) 2001-12-12
HUP0201856A1 (en) 2002-09-28
EP1419774A1 (en) 2004-05-19
DE10084709T1 (de) 2002-09-26
SK18172001A3 (sk) 2002-07-02
WO2000076506A1 (en) 2000-12-21
SI20850A (sl) 2002-10-31
LU90859B1 (en) 2002-01-24
IS6202A (is) 2001-12-14
NZ515783A (en) 2004-05-28
NO20015931D0 (no) 2001-12-04
ES2197792A1 (es) 2004-01-01
KR20020016831A (ko) 2002-03-06
LT2001119A (en) 2002-07-25
AU774175B2 (en) 2004-06-17
FI20012462L (fi) 2002-01-16
BG106221A (bg) 2002-08-30
ES2197792B1 (es) 2005-05-01
JP2003501467A (ja) 2003-01-14
BR0012082A (pt) 2002-05-07
SE0104203L (sv) 2001-12-14
TR200103613T2 (tr) 2004-08-23
HRP20010926A2 (en) 2003-04-30
CA2374877C (en) 2004-04-13
EP1183027A4 (en) 2003-02-05
FI20012462A7 (fi) 2002-01-16

Similar Documents

Publication Publication Date Title
CA2374877C (en) Pharmaceutical formulations and methods comprising intranasal morphine
AU775112B2 (en) Compositions and methods comprising morphine gluconate
JP2003501468A (ja) アポモルヒネの経鼻送達
NZ213067A (en) Composition for transdermal delivery of opioids
JP2016529328A (ja) 舌下ブプレノルフィンスプレー
US20090246273A1 (en) Ketorolac Sublingual Spray for the Treatment of Pain
EP2288334A1 (en) Composition and method for transmucosal delivery of lofexidine
US9283220B2 (en) Compositions of opioid antagonists and methods for treating conditions caused by the varicella-zoster virus therewith
CA3130619C (en) Naloxone formulations for sublingual and/or buccal administration
US10874658B2 (en) Sublingual opioid formulations containing naloxone
JP2003512415A (ja) ガランタミン及び甘味剤を含む経口液剤
HK1062812A (en) Pharmaceutical formulations and methods comprising intranasal morphine
WO2000076507A1 (en) Method for increasing the solubility of morphine and pharmaceutical compositions prepared therefrom
US20070248667A1 (en) Tannate Compositions and Methods of Use
EP1027049A1 (en) Intranasal formulation containing scopolamine and method of treating motion sickness